ГЕДЕРС Николас Э. (US),ФОКС Барбара С. (US),ГЕРИН Гленн (US)
申请号：
RU2013101766/15
公开号：
RU2013101766A
申请日:
2011.06.16
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical composition comprising metirapol formulated for oral or topical administration to a patient. The pharmaceutical composition of claim 1, further comprising a second pharmaceutically active agent. The pharmaceutical composition of claim 2, wherein the second pharmaceutically active agent increases the expression or activity of GABA； It is a simulator of GABA； or inhibits GABA metabolism in a patient. 4. The pharmaceutical composition according to any one of paragraphs. 1-3, where metirapol is present in unit dosage form in an amount insufficient to lower plasma levels of cortisol in a patient. 5. The pharmaceutical composition according to any one of paragraphs. 1-3, where metirapol is conjugated to an agent that facilitates movement through the blood-brain barrier. 6. The pharmaceutical composition according to any one of paragraphs. 1-3, additionally containing an outflow inhibitor that helps to maintain metirapol levels in the brain, and / or an excipient containing one or more of: polyethylene glycol, glycerol and gelatin. 7. A pharmaceutical composition containing the first agent that purposefully acts on the hypothalamic-pituitary-adrenal (HPA) system, but does not significantly lower plasma cortisol, and a second agent that purposefully acts on the prefrontal cortex. 8. The pharmaceutical composition of claim 7, wherein the first agent is an agent that inhibits the expression or activity of corticotropin-releasing hormone (CRH) or adrenocorticotropic hormone (ACTH). The pharmaceutical composition according to claim 7, wherein the first agent is metirapone (Metopyron®), its active �1. Фармацевтическая композиция, содержащая метирапол, составленная для перорального или местного введения пациенту.2. Фармацевтическая композиция по п. 1, дополнительно содержащая второе фармацевтически активное средство.3. Фармацевтическая композиция по п. 2, где второе фармацевтически активное средство увеличивает экспрессию или активность ГАМК； представляет собо
